MedPath

吉林恒星科技制药有限公司

Ownership
-
Established
2014-08-19
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

118

NMPA:118

Drug Approvals

益肝颗粒

Approval Number
国药准字Z22025259
Approval Date
Oct 13, 2022
NMPA

Oryzanol Tablets

Product Name
谷维素片
Approval Number
国药准字H22022911
Approval Date
Sep 15, 2022
NMPA

Cinmetacin Enteric coated Capsules

Product Name
桂美辛肠溶胶囊
Approval Number
国药准字H22025412
Approval Date
Sep 7, 2022
NMPA

Cinnarizine Tablets

Product Name
桂利嗪片
Approval Number
国药准字H22023085
Approval Date
Sep 6, 2022
NMPA

心脑清软胶囊

Approval Number
国药准字Z20043169
Approval Date
Aug 25, 2022
NMPA

Compound Sulfaguanidine Tablets

Product Name
复方磺胺脒片
Approval Number
国药准字H22025408
Approval Date
Aug 15, 2022
NMPA

化痰平喘片

Approval Number
国药准字Z22023979
Approval Date
Apr 18, 2022
NMPA

Spironolactone Tablets

Product Name
螺内酯片
Approval Number
国药准字H22023086
Approval Date
Apr 17, 2022
NMPA

Compound Gentamycin Sulfate and Procaine Hydrochloride Sulfate Granules

Product Name
庆大霉素普鲁卡因维B12颗粒
Approval Number
国药准字H22025409
Approval Date
Apr 17, 2022
NMPA

Ribavirin Tablets

Product Name
利巴韦林片
Approval Number
国药准字H22025346
Approval Date
Aug 31, 2021
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 12
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.